Table 1.

PIVOT-02 tumor cohort enrollment. Patients with selected advanced solid tumors were enrolled in the PIVOT-02 Phase I/II trial. All patients analyzed in this retrospective study received the RP2D. All results reported here, unless otherwise specified, are of the IO-naïve cohort (n = 200). 1L = first-line therapy; 2L = second-line therapy

Tumor Type	n
1L melanoma (MEL)	31
Advanced melanoma progressing after adjuvant therapy	7
1L renal cell carcinoma (RCC)	37
Renal cell carcinoma (other)	3
1L Metastatic urothelial cancer (mUC)	37
1-2L Triple-negative breast cancer (TNBC)	33
1-2L non-small cell lung cancer (NSCLC)	49
Non-small cell lung cancer (other)	3
Immunotherapy (IO) Naïve	200

The bold in Table 1 is highlighting the sum of all patients across all tumor types (n=200) being immunotherapy-naive